ARS Pharmaceuticals, Inc. (SPRY) Balance Sheet
SPRY balance sheet, 2025
December 31, 2025 · U.S. dollars$327.7M assets = $213.4M liabilities + $114.3M equity
Both columns are drawn to the same scale: what SPRY owns equals what it owes plus shareholders’ equity. Hover a block for its value.
SPRY financial health
Descriptive bands, not a rating. Fiscal 2025.
SPRY balance sheet trends, 2018–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $27.5M2018 | $327.7M2025 | +42.4%/yr | |
| Total liabilities | $9.3M2018 | $213.4M2025 | +56.3%/yr | |
| Shareholders’ equity | $18.2M2018 | $114.3M2025 | +30.0%/yr | |
| Cash & short-term investments | $20.2M2018 | $245.0M2025 | +42.9%/yr | |
| Total debt | $7.7M2018 | $96.4M2025 | +43.4%/yr | |
| Net cash (debt) | $12.4M2018 | $148.6M2025 | +$136.2M | |
| Working capital | $15.6M2018 | $245.8M2025 | +$230.1M | |
| Book value per share | $0.552018 | $1.162025 | +11.2%/yr | |
| Current ratio | 4.042018 | 7.282025 | +3.24 | |
| Debt / equity | 0.432018 | 0.842025 | +0.42 | |
| Shares outstanding | 33.1M2018 | 98.6M2025 | +16.9%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
SPRY assets
SPRY liabilities and equity
SPRY debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
SPRY balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & short-term investments | $245.0M | $314.0M | $228.4M | $274.4M | $60.1M | $24.5M | $10.0M | $20.2M |
| Cash & equivalents | $41.3M | $50.8M | $71.0M | $210.5M | $60.1M | $24.5M | $10.0M | $20.2M |
| Short-term investments | $203.7M | $263.2M | $157.4M | $63.9M | $0 | — | — | — |
| Receivables | $26.3M | $9.2M | $795,000 | $1.0M | $1,000 | $384,000 | $0 | $0 |
| Inventory | $8.4M | $5.2M | $0 | −$1.0M | −$6.8M | −$2.6M | $0 | $0 |
| Other current assets | $5.2M | $5.9M | $2.4M | $3.3M | $7.4M | $4.1M | $552,000 | $618,000 |
| Total current assets | $284.9M | $334.3M | $231.6M | $277.7M | $60.7M | $26.4M | $10.5M | $20.8M |
| Property, plant & equipment (net) | $2.5M | $1.1M | $824,000 | $774,000 | $693,000 | $23,000 | $4.6M | $6.0M |
| Goodwill & intangible assets | $14.5M | $7.7M | $617,000 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $25.8M | $8.1M | $184,000 | $3.0M | $23,000 | $2,000 | $550,000 | $750,000 |
| Total assets | $327.7M | $351.2M | $233.2M | $281.4M | $61.4M | $26.4M | $15.6M | $27.5M |
| Liabilities | ||||||||
| Accounts payable | $5.7M | $9.9M | $759,000 | $1.7M | $1.8M | $1.2M | $3.5M | $775,000 |
| Short-term debt | $588,000 | $42,000 | $237,000 | $230,000 | $3.6M | $2.6M | $12.3M | $3.5M |
| Deferred revenue | $609,000 | $557,000 | $4,000 | $283,000 | $1.5M | $3.5M | — | — |
| Total current liabilities | $39.1M | $23.4M | $2.4M | $5.4M | $8.2M | $8.2M | $17.9M | $5.1M |
| Long-term debt | $96.4M | $0 | $0 | $0 | $4.9M | $7.5M | $0 | $0 |
| Lease obligations | — | $42,000 | $274,000 | $481,000 | $624,000 | $0 | — | — |
| Other long-term liabilities | $77.9M | $70.9M | $36,999 | $3.1M | $79.6M | $24.8M | $3.3M | $4.2M |
| Total liabilities | $213.4M | $94.4M | $2.4M | $8.5M | $92.7M | $40.5M | $21.2M | $9.3M |
| Shareholders' equity | ||||||||
| Common stock & paid-in capital | $10,000 | $10,000 | $10,000 | $9,000 | $3,000 | $223,000 | — | — |
| Retained earnings (deficit) | −$294.6M | −$123.3M | −$131.3M | −$76.9M | −$42.3M | −$22.0M | −$63.8M | −$39.8M |
| Accumulated other comprehensive income | $125,000 | $220,000 | $49,000 | $406,999 | −$326,000 | −$21.2M | — | — |
| Total shareholders' equity | $114.3M | $256.8M | $230.8M | $272.9M | −$31.3M | −$14.1M | −$5.6M | $18.2M |
| Key figures | ||||||||
| Total debt | $96.4M | $42,000 | $274,000 | $481,000 | $9.0M | $10.0M | $15.6M | $7.7M |
| Net cash (debt) | $148.6M | $314.0M | $228.1M | $273.9M | $51.0M | $14.5M | −$5.6M | $12.4M |
| Working capital | $245.8M | $310.9M | $229.2M | $272.3M | $52.5M | $18.2M | −$7.4M | $15.6M |
| Tangible book value | $99.8M | $249.1M | $230.1M | $272.9M | −$31.3M | −$14.1M | −$5.6M | $18.2M |
| Book value per share | $1.16 | $2.51 | $2.42 | $6.83 | −$1.08 | −$0.40 | −$0.17 | $0.55 |
| Shares outstanding | 98.6M | 102.4M | 95.2M | 40.0M | 28.9M | 34.7M | 33.1M | 33.1M |
| Current ratio | 7.28 | 14.26 | 96.85 | 51.01 | 7.42 | 3.21 | 0.59 | 4.04 |
| Quick ratio | 6.93 | 13.79 | 95.84 | 50.59 | 7.34 | 3.03 | 0.56 | 3.92 |
| Debt / equity | 0.84 | 0.00 | 0.00 | 0.00 | — | — | — | 0.43 |
| Equity / assets | 34.9% | 73.1% | 99.0% | 97.0% | −50.9% | −53.2% | −35.8% | 66.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $143.8M | $201.0M | $245.0M | $288.2M | $240.1M | $275.7M | $314.0M | $204.6M | $218.7M | $223.6M | $228.4M | $241.9M |
| Cash & equivalents | $8.2M | $24.3M | $41.3M | $59.6M | $51.5M | $39.9M | $50.8M | $39.7M | $36.6M | $56.0M | $71.0M | $60.5M |
| Short-term investments | $135.7M | $176.6M | $203.7M | $228.7M | $188.6M | $235.9M | $263.2M | $165.0M | $182.1M | $167.6M | $157.4M | $181.4M |
| Receivables | $46.8M | $29.5M | $26.3M | $37.7M | $26.1M | $10.3M | $9.2M | $1.2M | $542,000 | $618,000 | $795,000 | $814,000 |
| Inventory | $11.7M | $8.8M | $8.4M | $7.8M | $8.7M | $7.3M | $5.2M | $715,000 | $0 | $0 | $0 | −$814,000 |
| Other current assets | $9.1M | $6.0M | $5.2M | $5.2M | $6.5M | $10.6M | $5.9M | $2.2M | $1.5M | $2.0M | $2.4M | $2.6M |
| Total current assets | $211.5M | $245.2M | $284.9M | $338.9M | $281.4M | $303.9M | $334.3M | $208.8M | $220.7M | $226.2M | $231.6M | $244.5M |
| Property, plant & equipment (net) | $2.1M | $2.3M | $2.5M | $2.6M | $2.6M | $1.1M | $1.1M | $935,000 | $782,000 | $814,000 | $824,000 | $917,000 |
| Goodwill & intangible assets | $13.9M | $14.2M | $14.5M | $14.7M | $13.2M | $7.5M | $7.7M | $7.9M | $446,000 | $528,000 | $617,000 | $690,000 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $22.0M | $25.9M | $25.8M | $16.6M | $16.2M | $14.8M | $8.1M | $0 | $0 | $0 | $184,000 | $2.5M |
| Total assets | $249.5M | $287.6M | $327.7M | $372.8M | $313.5M | $327.3M | $351.2M | $217.6M | $222.0M | $227.6M | $233.2M | $248.6M |
| Liabilities | ||||||||||||
| Accounts payable | $59.7M | $4.7M | $5.7M | $8.4M | $15.6M | $4.1M | $9.9M | $8.3M | $3.3M | $839,000 | $759,000 | $3.0M |
| Short-term debt | — | $592,000 | $588,000 | $583,000 | $589,000 | $73,000 | $42,000 | $102,000 | $160,000 | $217,000 | $237,000 | $235,000 |
| Deferred revenue | $535,000 | $757,000 | $609,000 | — | $746,000 | $540,000 | $557,000 | — | $13,000 | $47,000 | $4,000 | −$3.0M |
| Total current liabilities | $60.9M | $49.6M | $39.1M | $50.9M | $45.6M | $27.6M | $23.4M | $16.6M | $6.7M | $3.7M | $2.4M | $11.2M |
| Long-term debt | $96.7M | $96.5M | $96.4M | $96.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | — | — | $1.5M | $1.7M | $73,000 | $42,000 | $102,000 | $160,000 | $217,000 | $274,000 | $327,000 |
| Other long-term liabilities | $79.4M | $80.1M | $77.9M | $78.0M | $75.6M | $70.7M | $70.9M | $0 | $0 | $0 | $36,999 | $92,000 |
| Total liabilities | $237.0M | $226.3M | $213.4M | $225.1M | $121.2M | $98.3M | $94.4M | $16.6M | $6.7M | $3.7M | $2.4M | $11.3M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $10,000 | $10,000 | $10,000 | $10,000 | $10,000 | $10,000 | $10,000 | $10,000 | $10,000 | $10,000 | $10,000 | $9,000 |
| Retained earnings (deficit) | −$417.6M | −$355.2M | −$294.6M | −$253.3M | −$202.1M | −$157.2M | −$123.3M | −$173.2M | −$154.1M | −$141.6M | −$131.3M | −$124.1M |
| Accumulated other comprehensive income | −$140,000 | −$96,000 | $125,000 | −$7,000 | −$46,000 | $72,000 | $220,000 | $339,000 | −$145,000 | −$124,000 | $49,000 | −$161,000 |
| Total shareholders' equity | $12.5M | $61.3M | $114.3M | $147.7M | $192.3M | $229.0M | $256.8M | $201.0M | $215.2M | $223.9M | $230.8M | $237.3M |
| Key figures | ||||||||||||
| Total debt | $171.6M | $96.5M | $96.4M | $1.5M | $1.7M | $73,000 | $42,000 | $102,000 | $160,000 | $217,000 | $274,000 | $327,000 |
| Net cash (debt) | −$27.8M | $104.4M | $148.6M | $286.7M | $238.5M | $275.7M | $314.0M | $204.5M | $218.6M | $223.4M | $228.1M | $241.6M |
| Working capital | $150.6M | $195.6M | $245.8M | $288.0M | $235.8M | $276.2M | $310.9M | $192.2M | $214.0M | $222.5M | $229.2M | $233.3M |
| Tangible book value | −$1.4M | $47.1M | $99.8M | $132.9M | $179.2M | $221.5M | $249.1M | $193.1M | $214.8M | $223.3M | $230.1M | $236.6M |
| Book value per share | $0.13 | $0.62 | $1.16 | $1.49 | $1.96 | $2.34 | $2.62 | $2.07 | $2.22 | $2.32 | $2.40 | $2.48 |
| Shares outstanding | 99.3M | 99.3M | 98.6M | 98.8M | 98.4M | 98.1M | 98.0M | 97.0M | 96.8M | 96.5M | 96.1M | 95.6M |
| Current ratio | 3.48 | 4.94 | 7.28 | 6.66 | 6.17 | 11.00 | 14.26 | 12.56 | 32.82 | 60.90 | 96.85 | 21.87 |
| Quick ratio | 3.13 | 4.64 | 6.93 | 6.41 | 5.84 | 10.35 | 13.79 | 12.38 | 32.61 | 60.36 | 95.84 | 21.71 |
| Debt / equity | 13.72 | 1.57 | 0.84 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity / assets | 5.0% | 21.3% | 34.9% | 39.6% | 61.4% | 70.0% | 73.1% | 92.4% | 97.0% | 98.4% | 99.0% | 95.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 9, 2026); data from EODHD.
SPRY financial position
At the end of fiscal 2025 (December 31, 2025), ARS Pharmaceuticals had total assets of $327.7 million (down 6.7% from a year earlier), total liabilities of $213.4 million and shareholders' equity of $114.3 million. It held $245.0 million in cash and short-term investments against $96.4 million of debt, a net cash position of $148.6 million. Its current ratio was 7.28. In the latest quarter (ended June 30, 2026) total assets were $249.5 million and equity $12.5 million.
Related: SPRY income statement, SPRY cash flow statement, SPRY key metrics. See the SPRY stock overview for the latest quote and news.
SPRY balance sheet FAQ
What are ARS Pharmaceuticals's total assets?
ARS Pharmaceuticals reported total assets of $327.7 million at the end of fiscal 2025 (December 31, 2025), compared with $351.2 million a year earlier.
How much debt does ARS Pharmaceuticals have?
ARS Pharmaceuticals had $96.4 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was 0.84.
How much cash does ARS Pharmaceuticals have?
ARS Pharmaceuticals held $245.0 million in cash and short-term investments at the end of fiscal 2025; with $96.4 million of debt that is net cash of $148.6 million.
What is ARS Pharmaceuticals's book value?
ARS Pharmaceuticals's shareholders' equity (book value) was $114.3 million at the end of fiscal 2025, or $1.16 per share.
What is ARS Pharmaceuticals's current ratio?
ARS Pharmaceuticals had current assets of $284.9 million and current liabilities of $39.1 million, a current ratio of 7.28 (it can cover its short-term obligations).
How much goodwill does ARS Pharmaceuticals have?
ARS Pharmaceuticals carried $14.5 million of goodwill and intangible assets, 4.4% of total assets, at the end of fiscal 2025.